MEIS1 Regulates Hemogenic Endothelial Generation, Megakaryopoiesis, and Thrombopoiesis in Human Pluripotent Stem Cells by Targeting TAL1 and FLI1

Overview

Journal Stem Cell Reports

Publisher Cell Press

Specialty Cell Biology

Date 2018 Jan 24

PMID 29358086

Citations 32

Authors

Hongtao Wang

Cuicui Liu

Xin Liu

Mengge Wang

Dan Wu

Jie Gao

Pei Su

Tatsutoshi Nakahata

Wen Zhou

Yuanfu Xu

Lihong Shi

Feng Ma

Jiaxi Zhou

Affiliations

Soon will be listed here.

Abstract

Human pluripotent stem cells (hPSCs) provide an unlimited source for generating various kinds of functional blood cells. However, efficient strategies for generating large-scale functional blood cells from hPSCs are still lacking, and the mechanism underlying human hematopoiesis remains largely unknown. In this study, we identified myeloid ectopic viral integration site 1 homolog (MEIS1) as a crucial regulator of hPSC early hematopoietic differentiation. MEIS1 is vital for specification of APLNR mesoderm progenitors to functional hemogenic endothelial progenitors (HEPs), thereby controlling formation of hematopoietic progenitor cells (HPCs). TAL1 mediates the function of MEIS1 in HEP specification. In addition, MEIS1 is vital for megakaryopoiesis and thrombopoiesis from hPSCs. Mechanistically, FLI1 acts as a downstream gene necessary for the function of MEIS1 during megakaryopoiesis. Thus, MEIS1 controls human hematopoiesis in a stage-specific manner and can be potentially manipulated for large-scale generation of HPCs or platelets from hPSCs for therapeutic applications in regenerative medicine.

Citing Articles

Integrated Multi-Level Investigation of Friend Leukemia Integration 1 Transcription Factor as a Novel Immune-Inflammatory Biomarker in Rheumatoid Arthritis: Bridging Bioinformatics, Clinical Cohorts, and Mechanistic Validation.

Zhang M, Wan L, Fang H, Zhang X, Wang S, Li F J Inflamm Res. 2025; 18:3105-3123.

PMID: 40059948 PMC: 11889415. DOI: 10.2147/JIR.S507941.

Insight into microRNAs' involvement in hematopoiesis: current standing point of findings.

Nassiri S, Ahmadi Afshar N, Almasi P Stem Cell Res Ther. 2023; 14(1):282.

PMID: 37794439 PMC: 10552299. DOI: 10.1186/s13287-023-03504-3.

ZEB2 and MEIS1 independently contribute to hematopoiesis via early hematopoietic enhancer activation.

Kitagawa Y, Ikenaka A, Sugimura R, Niwa A, Saito M iScience. 2023; 26(10):107893.

PMID: 37771659 PMC: 10522983. DOI: 10.1016/j.isci.2023.107893.

Cross-species transcriptomics reveals bifurcation point during the arterial-to-hemogenic transition.

Mo S, Qu K, Huang J, Li Q, Zhang W, Yen K Commun Biol. 2023; 6(1):827.

PMID: 37558796 PMC: 10412572. DOI: 10.1038/s42003-023-05190-6.

promotes lateral plate mesoderm formation by modulating the Wnt/β-catenin signaling pathway.

Wang D, Li Y, Xu C, Wang H, Huang X, Jin X iScience. 2023; 26(6):106917.

PMID: 37378343 PMC: 10291335. DOI: 10.1016/j.isci.2023.106917.

References

Copelan E . Hematopoietic stem-cell transplantation. N Engl J Med. 2006; 354(17):1813-26. DOI: 10.1056/NEJMra052638. View

Pineault N, Helgason C, Lawrence H, Humphries R . Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny. Exp Hematol. 2002; 30(1):49-57. DOI: 10.1016/s0301-472x(01)00757-3. View

Ariki R, Morikawa S, Mabuchi Y, Suzuki S, Nakatake M, Yoshioka K . Homeodomain transcription factor Meis1 is a critical regulator of adult bone marrow hematopoiesis. PLoS One. 2014; 9(2):e87646. PMC: 3911998. DOI: 10.1371/journal.pone.0087646. View

Zeddies S, Jansen S, Di Summa F, Geerts D, Zwaginga J, van der Schoot C . MEIS1 regulates early erythroid and megakaryocytic cell fate. Haematologica. 2014; 99(10):1555-64. PMC: 4181251. DOI: 10.3324/haematol.2014.106567. View

Ran D, Shia W, Lo M, Fan J, Knorr D, Ferrell P . RUNX1a enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells. Blood. 2013; 121(15):2882-90. PMC: 3624936. DOI: 10.1182/blood-2012-08-451641. View

Sandler V, Lis R, Liu Y, Kedem A, James D, Elemento O . Reprogramming human endothelial cells to haematopoietic cells requires vascular induction. Nature. 2014; 511(7509):312-8. PMC: 4159670. DOI: 10.1038/nature13547. View

Pang S, Wu Q, Tian S, Su P, Bai Y, Gao J . Establishment of a highly efficient hematopoietic differentiation model from human embryonic stem cells for functional screening. Sci China Life Sci. 2013; 56(12):1147-9. DOI: 10.1007/s11427-013-4567-0. View

Sim X, Poncz M, Gadue P, French D . Understanding platelet generation from megakaryocytes: implications for in vitro-derived platelets. Blood. 2016; 127(10):1227-33. PMC: 4786833. DOI: 10.1182/blood-2015-08-607929. View

Li Y, Luo H, Liu T, Zacksenhaus E, Ben-David Y . The ets transcription factor Fli-1 in development, cancer and disease. Oncogene. 2014; 34(16):2022-31. PMC: 5028196. DOI: 10.1038/onc.2014.162. View

10.

Kocabas F, Zheng J, Thet S, Copeland N, Jenkins N, DeBerardinis R . Meis1 regulates the metabolic phenotype and oxidant defense of hematopoietic stem cells. Blood. 2012; 120(25):4963-72. PMC: 3525021. DOI: 10.1182/blood-2012-05-432260. View

11.

Hisa T, Spence S, Rachel R, Fujita M, Nakamura T, Ward J . Hematopoietic, angiogenic and eye defects in Meis1 mutant animals. EMBO J. 2004; 23(2):450-9. PMC: 1271748. DOI: 10.1038/sj.emboj.7600038. View

12.

Miller M, Rosten P, Lemieux M, Lai C, Humphries R . Meis1 Is Required for Adult Mouse Erythropoiesis, Megakaryopoiesis and Hematopoietic Stem Cell Expansion. PLoS One. 2016; 11(3):e0151584. PMC: 4795694. DOI: 10.1371/journal.pone.0151584. View

13.

Vo L, Daley G . De novo generation of HSCs from somatic and pluripotent stem cell sources. Blood. 2015; 125(17):2641-8. PMC: 4408289. DOI: 10.1182/blood-2014-10-570234. View

14.

Gonzalez-Lazaro M, Rosello-Diez A, Delgado I, Carramolino L, Sanguino M, Giovinazzo G . Two new targeted alleles for the comprehensive analysis of Meis1 functions in the mouse. Genesis. 2014; 52(12):967-75. DOI: 10.1002/dvg.22833. View

15.

Cai M, Langer E, Gill J, Satpathy A, Albring J, Kc W . Dual actions of Meis1 inhibit erythroid progenitor development and sustain general hematopoietic cell proliferation. Blood. 2012; 120(2):335-46. PMC: 3628121. DOI: 10.1182/blood-2012-01-403139. View

16.

Inoue H, Nagata N, Kurokawa H, Yamanaka S . iPS cells: a game changer for future medicine. EMBO J. 2014; 33(5):409-17. PMC: 3989624. DOI: 10.1002/embj.201387098. View

17.

Wang C, Tang X, Sun X, Miao Z, Lv Y, Yang Y . TGFβ inhibition enhances the generation of hematopoietic progenitors from human ES cell-derived hemogenic endothelial cells using a stepwise strategy. Cell Res. 2011; 22(1):194-207. PMC: 3351921. DOI: 10.1038/cr.2011.138. View

18.

Mendjan S, Mascetti V, Ortmann D, Ortiz M, Karjosukarso D, Ng Y . NANOG and CDX2 pattern distinct subtypes of human mesoderm during exit from pluripotency. Cell Stem Cell. 2014; 15(3):310-325. DOI: 10.1016/j.stem.2014.06.006. View

19.

Chou B, Mali P, Huang X, Ye Z, Dowey S, Resar L . Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res. 2011; 21(3):518-29. PMC: 3193421. DOI: 10.1038/cr.2011.12. View

20.

Elcheva I, Brok-Volchanskaya V, Kumar A, Liu P, Lee J, Tong L . Direct induction of haematoendothelial programs in human pluripotent stem cells by transcriptional regulators. Nat Commun. 2014; 5:4372. PMC: 4107340. DOI: 10.1038/ncomms5372. View